<div id="readability-page-1"><div>COPENHAGEN, Denmark – May 5, 2026. In the first quarter of 2026, Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.8%.Ester Baiget, President &amp; CEO:<div>“The year started strong with 7% organic sales growth against a high comparable. We delivered growth across all sales areas and in both Developed and Emerging markets, while achieving an adjusted EBITDA margin of 37.8%. Quarter after quarter, our results demonstrate the strength and resilience of our business model. Even with increased global uncertainty, we are confident in our full-year outlook and in our 2030 targets, including a 6–9% organic sales growth CAGR. As the world continues to change, the relevance and demand for biosolutions continue to grow.&#34;</div>Highlights of our Q1 2026 results:• Strong broad-based organic sales growth of 7% including ~1.5 pp effect from exiting certain countries. Price and revenue synergies contributed ~1 pp each.• Food &amp; Health Biosolutions grew 9% organically including ~3 pp effect from exiting certain countries; Planetary Health Biosolutions grew 5% organically.• Developed Markets grew 8% organically and Emerging Markets 4% including ~3 pp effect from exiting certain countries.• Adjusted EBITDA margin at 37.8% including a significant year-on-year currency headwind.• Adjusted net profit excl. PPA increased 8%.• NIBD/EBITDA at 2.0x, and free cash flow before acquisitions increased 9% to EUR 74 million. CAPEX ratio at 8.3%.• Successful inaugural bond issuance of EUR 1.7 billion completed to refinance a bridge loan facility.• Acquisition of a production facility in Thailand to support growth journey.• 2026 outlook confirmed:Organic sales growth is expected to be in the range of 5-7% which includes a close to 1 pp effect from exiting certain countries. Adjusted EBITDA margin expected to be between 37-38%.Here is the link to the investor call on Novonesis Q1 2026 results: https://getvisualtv.net/stream/?novonesis-interim-report-q1-2026Get in touchMedia relationsBenjamin HjorthSenior Press Managermedia-relations@novonesis.com+45 30 77 13 12Tobias BjorklundHead of Investor Relationstobb@novonesis.com</div></div>

NVNXF

In Q1 2026, Novonesis reported a 7% organic sales growth and an adjusted EBITDA margin of 37.8%. The growth was broad-based across all sales areas, with Developed Markets growing 8% and Emerging Markets 4%. The company confirmed its 2026 outlook, expecting organic sales growth of 5-7% and an adjusted EBITDA margin of 37-38%. Additionally, Novonesis completed a EUR 1.7 billion bond issuance and acquired a production facility in Thailand to support its growth strategy.

Novonesis delivered strong start to the year with 7% organic sales growth in Q1